ArticleFrontiers in antibiotics2026
Antibiogram of pathogenic bacterial isolates from various samples in Prince Sultan Hospital, Western Region, Saudi Arabia. Retrospective study from 2020 to 2024.
Article in Frontiers in antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibiograms support empirical therapy by providing local antimicrobial susceptibility data, guiding clinical decisions, and stewardship efforts. Rising multidrug-resistant (MDR) bacteria highlight the importance of continuous antimicrobial resistance (AMR) surveillance to inform local treatment guidelines. Objectives: The purpose of this study was to assess AMR rates in clinical pathogenic isolates obtained from community-acquired infections at a general hospital in Western Saudi Arabia. Methods: Antibiogram data were analyzed retrospectively from January 2020 to September 2024, focusing on pathogenic bacteria and AMR isolates. Results and conclusion: This study shows high rates of ESBL-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.